BioNTech says bispecific antibody BNT324 is competitive against Summit's ivonescimab

1 month ago 5

• Healthcare

Victor Golmer

BNT324, a bispecific antibody candidate under development by BioNTech (NASDAQ:BNTX) that is seen as critical to the biotech's future success, will compete favorably against rival Summit Therapeutics' (NASDAQ:SMMT) ivonescimab, according to a BioNTech exec.

Speaking at the FT Live US

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. BioNTech says bispecific antibody BNT324 is competitive against Summit's ivonescimab